JP2020530272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530272A5 JP2020530272A5 JP2019572456A JP2019572456A JP2020530272A5 JP 2020530272 A5 JP2020530272 A5 JP 2020530272A5 JP 2019572456 A JP2019572456 A JP 2019572456A JP 2019572456 A JP2019572456 A JP 2019572456A JP 2020530272 A5 JP2020530272 A5 JP 2020530272A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1710835.8 | 2017-07-05 | ||
| GBGB1710835.8A GB201710835D0 (en) | 2017-07-05 | 2017-07-05 | ROR1 Antibodies |
| PCT/GB2018/051914 WO2019008377A1 (en) | 2017-07-05 | 2018-07-05 | ANTIBODY ROR1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530272A JP2020530272A (ja) | 2020-10-22 |
| JP2020530272A5 true JP2020530272A5 (hr) | 2021-08-12 |
| JP7242573B2 JP7242573B2 (ja) | 2023-03-20 |
Family
ID=59592560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572456A Active JP7242573B2 (ja) | 2017-07-05 | 2018-07-05 | Ｒｏｒ１抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11466083B2 (hr) |
| EP (1) | EP3649152A1 (hr) |
| JP (1) | JP7242573B2 (hr) |
| CN (1) | CN110891973B (hr) |
| AU (1) | AU2018297630A1 (hr) |
| CA (1) | CA3068196A1 (hr) |
| GB (1) | GB201710835D0 (hr) |
| MX (1) | MX2019015348A (hr) |
| WO (1) | WO2019008377A1 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| US20230416942A1 (en) * | 2020-08-21 | 2023-12-28 | Yale University | Nanobody Compositions and Methods of Use of the Same |
| AU2021334677A1 (en) * | 2020-08-24 | 2023-03-02 | Epimab Biotherapeutics (Hk) Limited | Anti-ROR1 antibodies and related bispecific binding proteins |
| CN116323946A (zh) * | 2020-09-03 | 2023-06-23 | 和铂医药(上海)有限责任公司 | 靶向ror1的抗体或其抗原结合片段及制备方法和应用 |
| EP4247848A1 (en) * | 2020-11-23 | 2023-09-27 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| WO2022182562A1 (en) * | 2021-02-23 | 2022-09-01 | BioLegend, Inc. | ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS |
| CN115151572B (zh) * | 2021-07-23 | 2023-09-15 | 浙江时迈药业有限公司 | 针对ror1的抗体及其用途 |
| CN113956359B (zh) * | 2021-10-29 | 2022-09-16 | 叶鑫淼 | 一种抗体及其在抗肿瘤中的应用 |
| WO2023125619A1 (zh) * | 2021-12-28 | 2023-07-06 | 江苏恒瑞医药股份有限公司 | 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途 |
| WO2024012434A1 (en) * | 2022-07-11 | 2024-01-18 | Hansoh Bio Llc | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| CN115724973B (zh) * | 2022-09-26 | 2023-07-11 | 普健生物（武汉）科技有限公司 | 抗人ror1高亲和力兔单克隆抗体及其应用 |
| CN116903740B (zh) * | 2023-04-21 | 2024-04-30 | 星奕昂(上海)生物科技有限公司 | 靶向ror1的抗体及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040220A1 (en) | 2003-10-16 | 2005-05-06 | Micromet Ag | Multispecific deimmunized cd3-binders |
| WO2007146957A2 (en) | 2006-06-13 | 2007-12-21 | Irm Llc | Ror1 as a therapeutic target for lung cancer |
| WO2010124188A1 (en) * | 2009-04-23 | 2010-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| EP2496605A1 (en) * | 2009-11-02 | 2012-09-12 | Oxford Biotherapeutics Ltd. | Ror1 as therapeutic and diagnostic target |
| CN102712695B (zh) | 2009-12-18 | 2015-01-21 | 堪瑟拉公司 | 能够诱导细胞死亡的ror1生物抑制剂 |
| EP3828205A1 (en) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| CA2818992C (en) | 2010-12-01 | 2021-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| US9217040B2 (en) | 2011-01-14 | 2015-12-22 | The Regents Of The University Of California | Therapeutic antibodies against ROR-1 protein and methods for use of same |
| EP3824905A1 (en) | 2012-08-20 | 2021-05-26 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| DK2888283T3 (en) * | 2012-08-24 | 2018-11-19 | Univ California | ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| CN113416252A (zh) | 2014-05-29 | 2021-09-21 | 宏观基因有限公司 | 三特异性结合分子和其使用方法 |
| MX367787B (es) * | 2014-07-29 | 2019-09-06 | Cellectis | Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer. |
| CA2956482A1 (en) | 2014-07-31 | 2016-02-04 | Cellectis | Ror1 specific multi-chain chimeric antigen receptor |
| CN106999576B (zh) | 2014-09-08 | 2021-09-03 | 国立癌症研究中心 | 癌细胞特异性抗体、抗癌剂、及癌症的检查方法 |
| AU2015329965A1 (en) | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 |
| JP2017536341A (ja) | 2014-10-09 | 2017-12-07 | エンクマフ アーゲー | 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体 |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| CN107428833B (zh) * | 2015-01-16 | 2021-11-02 | 朱诺治疗学股份有限公司 | Ror1特异性抗体和嵌合抗原受体 |
| EP3253754B1 (en) | 2015-02-02 | 2021-03-31 | Kancera AB | 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity |
| CN107847596B (zh) * | 2015-05-18 | 2022-05-31 | 优瑞科生物技术公司 | 抗ror1抗体 |
| JP2018521004A (ja) | 2015-05-18 | 2018-08-02 | ユーリカ セラピューティックス， インコーポレイテッド | 抗ｒｏｒ１キメラ抗原受容体 |
| AU2016345681A1 (en) | 2015-10-30 | 2018-05-10 | Nbe-Therapeutics Ag | Anti-ROR1 antibodies |
| JP7000660B2 (ja) | 2016-01-20 | 2022-02-04 | ザ スクリプス リサーチ インスティテュート | Ｒｏｒ１抗体組成物及び関連の方法 |
| AU2017209099A1 (en) | 2016-01-22 | 2018-08-02 | Janssen Biotech, Inc. | Anti-ROR1 antibodies, ROR1 x CD3 bispecific antibodies, and methods of using the same |
| TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ｒｏｒ１－結合分子及其使用方法 |
| WO2017156479A1 (en) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| JP6891262B2 (ja) | 2016-07-11 | 2021-06-18 | カンセラ・アーベー | 哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニルイミダゾ［４，５−ｂ］ピリジン−７−アミン誘導体 |
| US20200338210A1 (en) | 2016-12-22 | 2020-10-29 | Ardeagen Corporation | Anti-ror1 antibody and conjugates thereof |
| CN111263643A (zh) | 2017-05-23 | 2020-06-09 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和ror1或ror2的蛋白质 |
| MX2019015057A (es) | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
| US11518815B2 (en) | 2017-06-25 | 2022-12-06 | Systimmune, Inc. | Anti-ROR1 antibodies and methods of making and using thereof |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| WO2019016381A1 (en) | 2017-07-20 | 2019-01-24 | Nbe-Therapeutics Ag | MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES |
| SG11202000846WA (en) | 2017-08-07 | 2020-02-27 | Nbe Therapeutics Ag | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| CN111741757B (zh) | 2017-11-03 | 2023-12-19 | 莱蒂恩技术公司 | 用于用抗ror1免疫治疗来治疗癌症的组合物和方法 |
| GB201721802D0 (en) | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| WO2019225777A1 (ko) | 2018-05-23 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-ror1 항체 및 그 용도 |
-
2017
- 2017-07-05 GB GBGB1710835.8A patent/GB201710835D0/en not_active Ceased
-
2018
- 2018-07-05 US US16/628,512 patent/US11466083B2/en active Active
- 2018-07-05 CN CN201880045361.4A patent/CN110891973B/zh active Active
- 2018-07-05 MX MX2019015348A patent/MX2019015348A/es unknown
- 2018-07-05 WO PCT/GB2018/051914 patent/WO2019008377A1/en unknown
- 2018-07-05 JP JP2019572456A patent/JP7242573B2/ja active Active
- 2018-07-05 EP EP18742575.6A patent/EP3649152A1/en active Pending
- 2018-07-05 CA CA3068196A patent/CA3068196A1/en active Pending
- 2018-07-05 AU AU2018297630A patent/AU2018297630A1/en active Pending
-
2022
- 2022-07-21 US US17/869,872 patent/US20230220073A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530272A5 (hr) | ||
| JP2020529839A5 (hr) | ||
| RU2018124602A (ru) | Новые анти-pd-l1 антитела | |
| RU2504551C2 (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| Gupta et al. | Development of an EGFRvIII specific recombinant antibody | |
| JP6715770B2 (ja) | モノクローナル抗ｔｋ１抗体 | |
| IL276695A (en) | Antibodies, pharmaceuticals and their uses | |
| JP2020522513A5 (hr) | ||
| JP2020534830A5 (hr) | ||
| JP2020529838A5 (hr) | ||
| JP2019523651A5 (hr) | ||
| RU2013125306A (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| JP2008538182A5 (hr) | ||
| RU2020136055A (ru) | Kir3dl3 в качестве рецептора hhla2, анти-hhla2-антител и его использование | |
| JP2012505659A5 (hr) | ||
| JP2018520668A5 (hr) | ||
| JP2018535649A5 (hr) | ||
| WO2022152185A1 (zh) | 靶向cd5的全人源抗体 | |
| JP2009507471A5 (hr) | ||
| WO2019107671A1 (ko) | 항-ros1 항체 및 그의 용도 | |
| JP2019510506A (ja) | 抗ポドカリキシン様タンパク質前駆体サブタイプ２モノクローナル抗体とその生成方法及び使用 | |
| RU2016129166A (ru) | Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии | |
| RU2017123022A (ru) | Гуманизованные антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой тарапии | |
| WO2018135653A1 (ja) | 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出 |